26.01 USD
-0.21
0.80%
At close May 14, 4:00 PM EDT
After hours
26.01
+0.00
0.00%
1 day
-0.80%
5 days
-0.95%
1 month
4.04%
3 months
6.21%
6 months
-3.42%
Year to date
0.04%
1 year
-14.13%
5 years
-49.97%
10 years
-86.60%
 

About: Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Employees: 8,379

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

489% more call options, than puts

Call options by funds: $63.2M | Put options by funds: $10.7M

23% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 47

22% more funds holding in top 10

Funds holding in top 10: 9 [Q3] → 11 (+2) [Q4]

2.42% more ownership

Funds ownership: 95.78% [Q3] → 98.2% (+2.42%) [Q4]

2% more funds holding

Funds holding: 345 [Q3] → 353 (+8) [Q4]

1% more capital invested

Capital invested by funds: $3.43B [Q3] → $3.45B (+$18.2M) [Q4]

13% less repeat investments, than reductions

Existing positions increased: 118 | Existing positions reduced: 136

Research analyst outlook

We haven’t received any recent analyst ratings for PRGO.

Financial journalist opinion

Based on 12 articles about PRGO published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Perrigo (PRGO) Reliance on International Sales: What Investors Need to Know
Evaluate Perrigo's (PRGO) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Perrigo (PRGO) Reliance on International Sales: What Investors Need to Know
Neutral
Zacks Investment Research
1 week ago
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
Neutral
Seeking Alpha
1 week ago
Perrigo Company plc (PRGO) Q1 2025 Earnings Call Transcript
Perrigo Company plc (NYSE:PRGO ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations Patrick Lockwood-Taylor - President & Chief Executive Officer Eduardo Bezerra - Chief Financial Officer Conference Call Participants Susan Anderson - Canaccord Genuity Keith Devas - Jefferies Daniel Biolsi - Hedgeye Operator Good morning, ladies and gentlemen and welcome to the Perrigo Q1 2025 Financial Results Conference Call. At this time, all lines are in listen-only mode.
Perrigo Company plc (PRGO) Q1 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
1 week ago
Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Perrigo (PRGO) Reports Q1 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
1 week ago
Perrigo (PRGO) Q1 Earnings Beat Estimates
Perrigo (PRGO) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.29 per share a year ago.
Perrigo (PRGO) Q1 Earnings Beat Estimates
Neutral
PRNewsWire
1 week ago
Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations
Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN , May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested businesses, exited product lines and currency translation.
Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations
Negative
Zacks Investment Research
1 week ago
Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?
PRGO's first-quarter top line is likely to have been impacted by exited businesses and product lines, and unfavorable currency movements.
Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?
Neutral
Zacks Investment Research
2 weeks ago
Perrigo (PRGO) Earnings Expected to Grow: Should You Buy?
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo (PRGO) Earnings Expected to Grow: Should You Buy?
Neutral
PRNewsWire
2 weeks ago
Perrigo Announces Quarterly Dividend
DUBLIN , April 30, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on June 17, 2025, to shareholders of record on May 30, 2025. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.
Perrigo Announces Quarterly Dividend
Positive
Seeking Alpha
2 weeks ago
Perrigo: Opill Shows Where The Company Wants To Be
Perrigo's transformation from a low-margin generics manufacturer to a branded consumer self-care company hinges on the success of products like Opill and Mederma. Despite short-term revenue declines, Perrigo's margin expansion and cost-saving initiatives show promise for long-term growth and strategic focus. The company's financial health is under pressure, with high leverage and volatile infant formula business posing significant risks.
Perrigo: Opill Shows Where The Company Wants To Be
Charts implemented using Lightweight Charts™